The strength of an
integrated business model
Our current clinical pipeline includes differentiated assets that either target unmet medical need or that may have meaningful advantages relative to existing vaccine options.
VLA15 is the only vaccine in clinical development against Lyme disease, the most common tick-borne infection in the northern hemisphere.
VLA1553 is a single injection vaccine against chikungunya, a mosquito-borne disease that is highly prevalent in tropical and subtropical regions.
VLA2001 is the only COVID-19 inactivated and adjuvanted whole-virus vaccine currently in clinical development in Europe.
Our manufacturing base in Europe provides a long-term and sustainable industrial network to supply commercial and clinical products. We operate three manufacturing sites augmented by contract manufacturing partners.
Valneva has a specialist commercial infrastructure for the distribution of its travelers’ vaccines in key markets.
Franck GrimaudDirecteur Général & Chief Business Officer